Arena Pharmaceuticals (FRA:RN3N) Additional Paid-In Capital : €2,475.94 Mil(As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Additional Paid-In Capital?

Arena Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2021 (€2,276.88 Mil) to Sep. 2021 (€2,353.78 Mil) and increased from Sep. 2021 (€2,353.78 Mil) to Dec. 2021 (€2,475.94 Mil).

Arena Pharmaceuticals's annual additional paid-in capital increased from Dec. 2019 (€1,955.84 Mil) to Dec. 2020 (€2,126.92 Mil) and increased from Dec. 2020 (€2,126.92 Mil) to Dec. 2021 (€2,475.94 Mil).

Arena Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Arena Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Additional Paid-In Capital Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Additional Paid-In Capital

Get a 7-Day Free Trial

1,435.27

1,852.02

1,955.84

2,126.92

2,475.94

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Additional Paid-In Capital	Get a 7-Day Free Trial															2,126.92	2,278.02	2,276.88	2,353.78	2,475.94

Arena Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Arena Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines